在小鼠模型中异源初免-加强免疫对副结核提供更优保护
本研究在小鼠模型中评价副结核候选疫苗6611株联合两种佐剂及重组改良安卡拉痘苗病毒MVA85A异源加强的免疫效果。结果显示6611+ISA201初免后MVA85A加强可增强IFNγ、Th1/Th17细胞因子及IgG2b、IgG3应答,并在Map攻击后获得最高保护水平(最低CFU计数和肝脏病变评分)。
要点
- 6611+ISA201初免后MVA85A加强增强IFNγ、Th1/Th17细胞因子及IL-6、IL-4、IL-10产生。
- 该组IgG2b和IgG3同型抗体水平最高,二者对小鼠模型抗Map感染保护重要。
- 异源方案在Map攻击后保护最高,表现为最低CFU计数和肝脏病变评分。
核心结论
- 6611株+ISA201初免及MVA85A加强的异源方案在小鼠中诱导最高保护水平,结果鼓励在牛中进一步评价。
研究设计与样本
- 小鼠模型研究,评价副结核候选疫苗6611株联合两种佐剂及MVA85A异源加强的免疫原性和保护效果。
主要发现
- 6611+IFA初免后MVA85A加强未提高血清总IgG或特异性同型抗体。
- 6611+ISA201初免后MVA85A加强增强IFNγ、Th1/Th17细胞因子(IL-2、TNF、IL-17A)及IL-6、IL-4、IL-10产生。
- 6611+ISA201初免后MVA85A加强组IgG2b和IgG3同型抗体水平最高。
- 异源方案在Map攻击后CFU计数最低、肝脏病变评分最低。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is the best strategy to control Paratuberculosis (PTB), which is a significant disease in cattle and sheep. Previously we showed the humoral and cellular immune response induced by a novel vaccine candidate against PTB based on the Argentinian Mycobacterium avium subspecies paratuberculosis (Map) 6611 strain. To improve 6611 immunogenicity and efficacy, we evaluated this vaccine candidate in mice with two different adjuvants and a heterologous boost with a recombinant modified vaccinia Ankara virus (MVA) expressing the antigen 85A (MVA85A). We observed that boosting with MVA85A did not improve total IgG or specific isotypes in serum induced by one or two doses of 6611 formulated with incomplete Freund's adjuvant (IFA). However, when 6611 was formulated with ISA201 adjuvant, MVA85A boost enhanced the production of IFNγ, Th1/Th17 cytokines (IL-2, TNF, IL-17A) and IL-6, IL-4 and IL-10. Also, this group showed the highest levels of IgG2b and IgG3 isotypes, both important for better protection against Map infection in the murine model. Finally, the heterologous scheme elicited the highest levels of protection after Map challenge (lowest CFU count and liver lesion score). In conclusion, our results encourage further evaluation of 6611 strain + ISA201 prime and MVA85A boost in bovines.
引用
- Colombatti Olivieri MA, Cuerda MX, Moyano RD, et al. Superior protection against paratuberculosis by a heterologous prime-boost immunization in a murine model. Vaccine. 2024. PMID: 38880691. doi:10.1016/j.vaccine.2024.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。